Oct. 3 at 5:52 PM
your
$CATX info’s off — here’s the right take: It’s a TAT platform company with 8+ active programs (NETs, FAP-α, melanoma, prostate).
Said no ORR? VMT-a-NET showed 57% at ASCO 2025 (vs ~13% SOC). Strong data + possible Phase 3 skip = a real edge.
If you didn’t know, now you do. Avoid outdated or false info by AI — it can hurt your credibility. And when promoting another ticker, it’d be better not to tag CATX just to piggyback.
